Last reviewed · How we verify

NCT05730153

Advanced Platelet-rich Fibrin Combined With Open Debridement in Management of Suprabony Periodontal Defects

Completed Phase 4 Last updated 27 March 2023
What this trial tests

Phase 4 trial testing advanced PRF in Periodontitis, Adult in 30 participants. Completed in 26 July 2022.

Timeline
21 November 2021
Primary endpoint
27 January 2022
26 July 2022

Quick facts

Lead sponsorOctober University for Modern Sciences and Arts
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment30
Start date21 November 2021
Primary completion27 January 2022
Estimated completion26 July 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

October University for Modern Sciences and Arts

Who can join

Adults 18 to 60, any sex, with Periodontitis, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

in this clinical trial, patients with periodontal defects will be treated with advanced platelet-rich fibrin in conjunction with open debridement

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Single-flap approach versus without concentrate growth factor in the treatment of periodontal supra-osseous defects: A randomized controlled clinical trial.
    El-Wakeel N, Mohamed Abd-Elaziz L. · · 2024 · cited 1× · PMID 38419996 · DOI 10.1016/j.sdentj.2023.11.015

Verify or expand the search:

Other recruiting trials for Periodontitis, Adult

Currently open trials in the same condition.

Other October University for Modern Sciences and Arts trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05730153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing